跳至主要内容
临床试验/NCT04064034
NCT04064034已完成不适用

Evaluation of the Diagnostic Potential a Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
60
试验地点
2
主要终点
Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood

研究概览

简要总结

Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
17 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such as surgery, radiation or chemotherapy.
  • Patients without pancreas cancer.
  • Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer.
  • Healthy adults with blood specimens in an existing biobank.
  • Patients with pancreatic cystic lesions.
  • Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic cystic lesions.

排除标准

  • Prior treatment for pancreas cancer.
  • Unable or unwilling to give consent.

结局指标

主要结局

Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood

时间窗: Baseline

Number of subjects with the presence and concentration of QSOX1 peptide found in the blood samples by the lateral flow assay (LFA) test

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Douglas O. Faigel

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验